|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM364982497 |
| 003 |
DE-627 |
| 005 |
20250305115825.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109846
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1216.xml
|
| 035 |
|
|
|a (DE-627)NLM364982497
|
| 035 |
|
|
|a (NLM)38007033
|
| 035 |
|
|
|a (PII)S1521-6616(23)00610-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Koga, Tomohiro
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease
|b A preclinical study in mice and a pilot study in humans
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.12.2023
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a The study aimed to investigate the therapeutic effects of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) on adult-onset Still's disease (AOSD), specifically focusing on arthritis and macrophage activation syndrome (MAS). We used mouse models to assess the impact of 5-ALA/SFC on collagen-induced arthritis (CIA) and MAS induced by synthetic oligonucleotides containing CpG motifs (CpG-S-ODN). Additionally, we conducted a pilot study with AOSD patients receiving prednisolone (PSL) treatment and 5-ALA/SFC administration to evaluate its efficacy and safety. The 5-ALA/SFC group exhibited significantly lower joint scores in CIA mice. In CpG-S-ODN-treated mice, 5-ALA/SFC administration led to reduced hemophagocytosis and splenomegaly. The anti-inflammatory properties of 5-ALA/SFC were attributed to the suppression of CCL4 and CXCL10 production in monocytes and the induction of M2 macrophages. AOSD patients treated with 5-ALA/SFC demonstrated successful PSL tapering without adverse events. Collectively, the administration of 5-ALA/SFC showed promising potential in ameliorating arthritis and MAS in AOSD patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a 5-aminolevulinic acid/sodium ferrous citrate
|
| 650 |
|
4 |
|a Adult-onset Still's disease
|
| 650 |
|
4 |
|a Collagen-induced arthritis
|
| 650 |
|
4 |
|a Macrophage activation syndrome
|
| 650 |
|
7 |
|a Aminolevulinic Acid
|2 NLM
|
| 650 |
|
7 |
|a 88755TAZ87
|2 NLM
|
| 700 |
1 |
|
|a Sumiyoshi, Remi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsuji, Yoshika
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kodama, Ken
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Endo, Yushiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Furukawa, Kaori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kawakami, Atsushi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 257(2023) vom: 15. Dez., Seite 109846
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:257
|g year:2023
|g day:15
|g month:12
|g pages:109846
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109846
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 257
|j 2023
|b 15
|c 12
|h 109846
|